(18.208.202.194)
Users online: 977    [ij] [ij] [ij] 
Email id
 

Asian Journal of Pharmaceutical Research
Year : 2017, Volume : 7, Issue : 4
First page : ( 230) Last page : ( 238)
Print ISSN : 2231-5683. Online ISSN : 2231-5691.
Article DOI : 10.5958/2231-5691.2017.00036.3

Review on Dipeptidyl Peptidase IV Inhibitors as a Newer Target for Diabetes Mellitus Treatment

Chandramore Kavita*

Institute of Chemical Technology, Mumbai

*Corresponding Author E-mail: kavitachandramore@gmail.com

Online published on 2 June, 2018.

Abstract

Diabetes Mellitus (Type 2) is a major health issue all over the world. It is rapidly growing metabolic disorder characterized by hyperglycaemia with disturbances in carbohydrate, fat and protein metabolism. According to the International Diabetes Federation, more than 380 million people in the world suffer from Diabetes and this number will rise beyond 592 million in less than 25 years. The main classes of anti-diabetic drugs (biguanides, sulphonylureas, α-glucosidase inhibitors, thiazolidinediones, meglitinides) have side effects like weight gain and hypoglycaemia which makes them unsuitable for long term use. Thus newer anti-diabetic agents are still in need. Dipeptidyl Peptidase IV inhibitors have been found to be effective in the treatment of Type 2 Diabetes. DPP IV plays a major role in glucose metabolism. It is responsible for inactivation of incretins like GLP-1. Dipeptidyl Peptidase IV inhibitors increase insulin secretion by enhancing the level of incretin hormones. These incretin hormones are responsible for maintaining postprandial blood glucose levels by stimulating insulin secretion.

Top

Keywords

Diabetes Mellitus, Anti-diabetic, DPP IV, incretinharmone.

Top

  
║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
445,453,612 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.